基于人工智能的病理学作为肝细胞癌患者对阿替利珠单抗-贝伐珠单抗敏感性的生物标志物:一项多中心回顾性研究
该多中心回顾性研究开发了基于人工智能的模型(ABRS-P),可从肝细胞癌组织切片直接预测ABRS表达。模型在外部验证中与ABRS评分相关(手术切除系列r=0.60,活检系列r=0.53)。在122例接受阿替利珠单抗-贝伐珠单抗治疗的患者中,ABRS-P高组(n=74)中位无进展生存期12个月(95%CI 7-未达到)显著长于ABRS-P低组(n=48)的7个月(95%CI 4-9),p=0.014。
要点
- ABRS-P模型在外部验证中与ABRS评分相关:手术切除系列r=0.60,活检系列r=0.53。
- ABRS-P高组中位无进展生存期12个月(95%CI 7-未达到)vs 低组7个月(95%CI 4-9),p=0.014。
- 空间转录组学显示ABRS-P高值区域ABRS评分及其他免疫效应分子上调。
核心结论
- 人工智能应用于肝细胞癌数字切片可作为接受阿替利珠单抗-贝伐珠单抗治疗患者无进展生存期的生物标志物。
- 该方法可用于开发针对靶向治疗的廉价快速生物标志物。
- 人工智能热图与空间转录组学结合可揭示与预测相关的分子特征。
研究设计与样本
- 多中心回顾性研究,开发ABRS-P模型,源自既往发表的聚类约束注意力多实例学习(CLAM)流程。
- 训练集来自癌症基因组图谱(The Cancer Genome Atlas)接受手术切除的患者n=336。
- 外部验证集包括两个独立系列:手术切除系列n=225和活检系列n=157。
- 预测价值在122例接受阿替利珠单抗-贝伐珠单抗治疗的多中心队列活检样本中进一步测试。
- 所有样本来自成人(年龄≥18岁),验证集采样时间为2008年1月1日至2023年1月1日。
主要发现
- 840例患者中,641例(76%)为男性,199例(24%)为女性。
- 开发系列交叉验证中,ABRS-P值与ABRS评分平均Pearson相关系数r=0.62(SD 0.09;平均p<0.0001,SD<0.0001)。
- 外部验证中,手术切除系列r=0.60(95%CI 0.51-0.68),p<0.0001;活检系列r=0.53(95%CI 0.40-0.63),p<0.0001。
- 122例接受阿替利珠单抗-贝伐珠单抗治疗的患者中,ABRS-P高组(n=74)中位无进展生存期12个月(95%CI 7-未达到)vs ABRS-P低组(n=48)7个月(95%CI 4-9),p=0.014。
- 空间转录组学显示,ABRS-P高值肿瘤区域较ABRS-P低值区域ABRS评分显著更高,且多种其他免疫效应分子上调。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical benefits of atezolizumab plus bevacizumab (atezolizumab-bevacizumab) are observed only in a subset of patients with hepatocellular carcinoma and the development of biomarkers is needed to improve therapeutic strategies. The atezolizumab-bevacizumab response signature (ABRS), assessed by molecular biology profiling techniques, has been shown to be associated with progression-free survival after treatment initiation. The primary objective of our study was to develop an artificial intelligence (AI) model able to estimate ABRS expression directly from histological slides, and to evaluate if model predictions were associated with progression-free survival. METHODS: In this multicentre retrospective study, we developed a model (ABRS-prediction; ABRS-P), which was derived from the previously published clustering-constrained attention multiple instance learning (or CLAM) pipeline. We trained the model fit for regression analysis using a multicentre dataset from The Cancer Genome Atlas (patients treated by surgical resection, n=336). The ABRS-P model was externally validated on two independent series of samples from patients with hepatocellular carcinoma (a surgical resection series, n=225; and a biopsy series, n=157). The predictive value of the model was further tested in a series of biopsy samples from a multicentre cohort of patients with hepatocellular carcinoma treated with atezolizumab-bevacizumab (n=122). All samples in the study were from adults (aged ≥18 years). The validation sets were sampled between Jan 1, 2008, to Jan 1, 2023. For the multicentre validation set, the primary objective was to assess the association of high versus low ABRS-P values, defined relative to cross-validation median split thresholds in the first biopsy series, with progression-free survival after treatment initiation. Finally, we performed spatial transcriptomics and matched prediction heatmaps with in situ expression profiles. FINDINGS: Of the 840 patients sampled, 641 (76%) were male and 199 (24%) were female. Across the development and validation datasets, hepatocellular carcinoma risk factors included alcohol intake, hepatitis B and C virus infections, and non-alcoholic steatohepatitis. Using cross-validation in the development series, the mean Pearson's correlation between ABRS-P values and ABRS score (mean expression of ABRS genes) was r=0·62 (SD 0·09; mean p<0·0001, SD<0·0001). The ABRS-P generalised well on the external validation series (surgical resection series, r=0·60 [95% CI 0·51-0·68], p<0·0001; biopsy series, r=0·53 [0·40-0·63], p<0·0001). In the 122 patients treated with atezolizumab-bevacizumab, those with ABRS-P-high tumours (n=74) showed significantly longer median progression-free survival than those with ABRS-P-low tumours (n=48) after treatment initiation (12 months [95% CI 7-not reached] vs 7 months [4-9]; p=0·014). Spatial transcriptomics showed significantly higher ABRS score, along with upregulation of various other immune effectors, in tumour areas with high ABRS-P values versus areas with low ABRS-P values. INTERPRETATION: Our study indicates that AI applied on hepatocellular carcinoma digital slides is able to serve as a biomarker for progression-free survival in patients treated with atezolizumab-bevacizumab. This approach could be used in the development of inexpensive and fast biomarkers for targeted therapies. The combination of AI heatmaps with spatial transcriptomics provides insight on the molecular features associated with predictions. This methodology could be applied to other cancers or diseases and improve understanding of the biological mechanisms that drive responses to treatments. FUNDING: Institut National du Cancer, Fondation ARC, China Scholarship Council, Ligue Contre le Cancer du Val de Marne, Fondation de l'Avenir, Ipsen, and Fondation Bristol Myers Squibb Pour la Recherche en Immuno-Oncologie.
引用
- Zeng Q, Klein C, Caruso S, et al. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study. Lancet Oncol. 2023. PMID: 37951222. doi:10.1016/S1470-2045(23)00468-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。